14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 AFMD stock ended at $5.42. This is 2.26% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.04% from a day low at $5.10 to a day high of $5.51.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Affimed N.V. prices

Date Open High Low Close Volume
Jul 24, 2020 $40.70 $41.80 $39.25 $39.40 130 403
Jul 23, 2020 $42.50 $42.67 $40.80 $41.10 67 570
Jul 22, 2020 $43.80 $44.30 $41.20 $42.30 97 680
Jul 21, 2020 $44.40 $44.60 $43.30 $44.05 69 450
Jul 20, 2020 $44.10 $45.00 $42.70 $43.90 78 420
Jul 17, 2020 $45.10 $46.10 $44.00 $44.15 198 420
Jul 16, 2020 $45.60 $46.10 $43.85 $45.10 161 540
Jul 15, 2020 $42.70 $46.15 $41.40 $45.70 183 770
Jul 14, 2020 $42.60 $43.46 $39.00 $41.60 200 430
Jul 13, 2020 $44.20 $45.00 $42.30 $42.30 87 770
Jul 10, 2020 $45.10 $47.30 $43.00 $44.10 117 220
Jul 09, 2020 $46.20 $49.10 $45.30 $46.00 125 970
Jul 08, 2020 $43.90 $45.80 $43.40 $45.80 73 580
Jul 07, 2020 $43.50 $45.07 $42.00 $43.90 142 170
Jul 06, 2020 $46.40 $47.04 $42.80 $43.40 128 760
Jul 02, 2020 $47.90 $47.90 $45.30 $45.70 109 301
Jul 01, 2020 $46.30 $47.90 $45.40 $47.30 101 615
Jun 30, 2020 $45.40 $46.50 $44.50 $46.15 124 284
Jun 29, 2020 $47.30 $47.60 $44.50 $45.10 166 868
Jun 26, 2020 $45.10 $47.70 $44.10 $46.30 408 577
Jun 25, 2020 $41.10 $46.45 $40.30 $46.30 162 696
Jun 24, 2020 $42.30 $44.08 $39.50 $40.90 154 405
Jun 23, 2020 $41.80 $44.06 $39.30 $42.50 170 801
Jun 22, 2020 $39.70 $46.60 $38.55 $44.10 375 519
Jun 19, 2020 $36.00 $39.60 $35.37 $38.80 232 833
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT